No Data
No Data
The HINSANG GROUP (06893) Shareholder transferred 47 million HKD Market Cap Stocks from Baoqiao Securities to Yuanta Securities Hong Kong, accounting for 22.9%.
On March 3, HINSANG GROUP (06893) Shareholders transferred 47 million HKD Market Cap Stocks from Baokiao Securities Limited to Yuanta Securities Hong Kong, accounting for 22.9%.
What does AI pharmaceuticals still lack before a market explosion? | Focus
① From the discovery of targets to the identification of preclinical candidate compounds, current generative AI mainly focuses on the early stages of drug development, which can lead to significant acceleration; ② If AI in drug development is to further expand the realm of possibilities, it must explore more profitable real-world applications.
HINSANG GROUP: Interim Report 2024/2025
hinsang group (06893.HK) mid-term revenue of approximately 46.21 million Hong Kong dollars decreased by about 11.7% year-on-year
On November 28, Hinsang Group (06893.HK) announced that for the six-month interim performance ending on September 30, 2024, the group's revenue was approximately HK$46.21 million, a decrease of about 11.7% from approximately HK$52.3 million in the same period of 2023. The group incurred a loss of HK$19.242 million during this period, a year-on-year increase of 83.9%; with a loss per share of 1.73 HK cents. The group is confident that the Hong Kong market can continue to provide a stable platform for its business growth and expansion. The group remains committed to new product development to enrich its portfolio of health supplements and enhance its brand image as a specialist in health supplements.
HINSANG GROUP: ANNOUNCEMENT ON INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024
Hin Sang Group (International) Holding Expects Wider Net Loss for Six Months to September